Novel role of SF1 in alleviating thyroid-associated ophthalmopathy through the AMPK/mTOR signaling pathway.

[1]  Kai Jin,et al.  Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis , 2018, BMC Ophthalmology.

[2]  Guangyao Wu,et al.  Overexpression of miR-185 inhibits autophagy and apoptosis of dopaminergic neurons by regulating the AMPK/mTOR signaling pathway in Parkinson's disease , 2017, Molecular medicine reports.

[3]  J. Ma,et al.  [Progression of the pathogenesis of thyroid associated ophthalmopathy]. , 2017, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.

[4]  Y. Gong,et al.  Transcription of CYP19A1 is directly regulated by SF-1 in the theca cells of ovary follicles in chicken. , 2017, General and comparative endocrinology.

[5]  Terry J. Smith,et al.  Teprotumumab for Thyroid‐Associated Ophthalmopathy , 2017, The New England journal of medicine.

[6]  M. Suyama,et al.  Role of Ad4-binding protein/steroidogenic factor 1 in regulating NADPH production in adrenocortical Y-1 cells. , 2017, Endocrine journal.

[7]  Yali Zhang,et al.  Icariin Inhibits AMPK-Dependent Autophagy and Adipogenesis in Adipocytes In vitro and in a Model of Graves' Orbitopathy In vivo , 2017, Front. Physiol..

[8]  A. Gotz-Więckowska,et al.  An update on thyroid-associated ophthalmopathy in children and adolescents , 2016, Journal of pediatric endocrinology & metabolism : JPEM.

[9]  Wencan Wu,et al.  Development of a Novel Thyroid Function Fluctuated Animal Model for Thyroid-Associated Ophthalmopathy , 2016, PloS one.

[10]  C. Chen,et al.  Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer – a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation , 2015, Oncotarget.

[11]  J. Qin,et al.  TMP21 modulates cell growth in papillary thyroid cancer cells by inducing autophagy through activation of the AMPK/mTOR pathway. , 2015, International journal of clinical and experimental pathology.

[12]  A. Latronico,et al.  DAX1 Overexpression in Pediatric Adrenocortical Tumors: A Synergic Role with SF1 in Tumorigenesis , 2015, Hormone and Metabolic Research.

[13]  Terry J. Smith,et al.  Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. , 2015, JAMA ophthalmology.

[14]  Terry J. Smith TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy , 2015, Nature Reviews Endocrinology.

[15]  M. Saji,et al.  A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. , 2015, The Journal of clinical endocrinology and metabolism.

[16]  O. Durrani,et al.  Are Ethnicity, Social Grade, and Social Deprivation Associated With Severity of Thyroid-Associated Ophthalmopathy? , 2014, Ophthalmic plastic and reconstructive surgery.

[17]  T. Ziegler,et al.  Steroidogenic factor 1 promotes aggressive growth of castration-resistant prostate cancer cells by stimulating steroid synthesis and cell proliferation. , 2014, Endocrinology.

[18]  D. Schlessinger,et al.  FOXL2 transcriptionally represses Sf1 expression by antagonizing WT1 during ovarian development in mice , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  J. Achermann,et al.  Steroidogenic Factor-1 and Human Disease , 2012, Seminars in Reproductive Medicine.

[20]  R. Medhamurthy,et al.  Luteinizing hormone regulates inhibin-α subunit expression through multiple signaling pathways involving steroidogenic factor-1 and beta-catenin in the macaque corpus luteum , 2012, Growth factors.

[21]  M. J. Vazquez,et al.  Hypothalamic mTOR pathway mediates thyroid hormone‐induced hyperphagia in hyperthyroidism , 2012, The Journal of pathology.

[22]  P. White,et al.  Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. , 2010, Molecular endocrinology.

[23]  S. Jyonouchi,et al.  Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. , 1999, The Journal of clinical endocrinology and metabolism.